Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK

Journal of Medical Economics

Volumn 5, Issue 51-64, 2002, Pages 51-64

  Odeyemi, Isaac A O ^a   Guest, Julian F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

Activated prothrombin complex; Costs; Economics; Factor VII; Haemophilia

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AMBULANCE; ARTICLE; BLEEDING; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH CARE UTILIZATION; HEMOPHILIA; HOSPITAL COST; HUMAN; INTERVIEW; OUTPATIENT CARE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0036304921     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200205051064     Document Type: Article

References (25)

1. The incidence of Factor VIII inhibitors in the UK, 1990-93
2. Early treatment with recombinant Factor VIIa results in greater efficacy with less product
3. Recombinant activated Factor VII for treatment of intramuscular haemorrhages: A comparison of early versus late treatment
4. Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: The advantages of early intervention
5. Efficacy of recombinant activated Factor VII when administered in the home to control joint, muscle, and mucocutaneous bleeds in haemophilia patients with inhibitors
6. Factor VIII inhibitor bypassing activity
7. Activated prothrombin concentrate for patients with Factor VIII inhibitors
8. Factor VIII inhibitor bypassing activity
9. Activated F IX concentrate (aPCC) used in the treatment of haemophilic patients with antibody to F VIII
10. The effect of activated prothrombin-complex concentrate (aPCC) on joint and muscle bleeding in patients with haemophilia A and antibodies to Factor VIII
11. The use of Factor eight inhibitor by-passing activity (aPCC Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors
12. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in haemophilia patients
13. Multicenter retrospective study on the utilisation of aPCC in France in patients with Factor VIII and Factor IX inhibitors
14. The aPCC-VH survey: Initial findings from a world-wide surveillance study
15. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with haemophilia A and inhibitors. The results of an international survey
16. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated Factor VII in a patient with severe haemophilia A and an anti-Factor VIII inhibitor
17. Economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a minor bleed in haemophilia patients with high titre high responding inhibitors to coagulation Factors VIII and IX
18. Consensus methods: Characteristics and guidelines for use
19. The economics of Factor VIII inhibitor treatment
20. Pharmaco-economic aspects of inhibitor treatment
21. Economic aspects of haemophilia care
22. Funding arrangements within the UK